A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors

A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors

BackgroundThe survival rates for pediatric patients with relapsed and refractory tumors are poor. Successful treatment strategies are currently lacking and there remains an unmet need for novel therapies for these patients. We report here the results of a phase 1 study of talimogene laherparepvec (T...

Full description

Bibliographic Details
Main Authors: Lucas Moreno, Pierre Teira, James M. Croop, Nicolas U. Gerber, Nicolas André, Isabelle Aerts, Luis Gros Subias, Bram De Wilde, Francisco Bautista, Brian Turpin, Srinivasa Kunduri, Ali Hamidi, Tatiana Lawrence, Keri A. Streby
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Pediatrics
Subjects:
immunotherapy
pediatric solid tumor
talimogene laherparepvec
non-CNS tumors
relapsed and refractory cancer
oncolytic herpes virus
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2023.1183295/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2023.1183295/full

Similar Items